3 New Strong Buy Ratings from Top-Rated Analysts: 02/10/2026

By Jessie Moore, Stock Researcher and Writer
February 10, 2026 5:35 AM UTC
3 New Strong Buy Ratings from Top-Rated Analysts: 02/10/2026

Here are three Strong Buy picks for 2/10/2026:

  • Eli Lilly & Co (LLY) is coasting on the obesity drug trend 
  • FedEx (FDX) enjoys e-commerce tailwinds + more
  • Woodward (WWD) enjoys fresh highs during the aerospace boom

P.S. Speaking of hot, have you seen our video featuring a historical chart that seems eerily prescient for 2026? Check it out here.


A note from our sponsors...

Buffett's $114 Secret In 1943, a teenage Warren Buffett put $114 into a special type of account called "The 29% Account." Today, that single, $114 investment would be worth over $15 million. Your bank never told you about this. Click Here to See How It Works

1. Eli Lilly & Co (NYSE: LLY)

This pharmaceutical giant is capitalizing on explosive growth in its diabetes and obesity segments, with a robust pipeline poised to deliver significant near-term catalysts including upcoming clinical trial results for new diabetes medications.

Zen Rating: B (Buy) see full analysis

Recent Price: $1,058.18 — get current quote

Max 1-year forecast: $1,500.00

Why we're watching:

  • Analyst support: Right now, LLY enjoys 11 Strong Buy ratings, 3 Buy ratings, and 3 Hold ratings out of 17 total analysts we track covering the stock. See the ratings
  • For example, JP Morgan's Chris Schott (top 12%) set a bullish $1,300 price target, emphasizing that Eli Lilly is set to benefit from strong product sales in their diabetes and obesity segments with a robust pipeline expected to convert into marketable products soon.
  • Wells Fargo analyst Mohit Bansal (top 14%) raised his price target to $1,280, highlighting that LLY is well positioned to sustain revenue growth due to unique products and growing market share, with a major product launch imminent that will substantially impact earnings.
  • Industry ranking context: LLY is currently the 5th highest-rated stock in the General Drug Manufacturer industry, which has an Industry Rating of A.
  • Zen Rating highlights: Buy (B) stocks average +19.88%/yr — with strong demand and a strong pipeline, this seems like a realistic range for LLY. 
  • Component Grades: LLY demonstrates exceptional performance across the 7 Component Grades that shape the overall rating, with above-average Bs for Value, Growth, Momentum, Financials, and from our proprietary AI Factor. See all 7 Zen Component Grades here

2. Woodward (NASDAQ: WWD)

The aerospace revolution is real, and it’s benefiting this company — which, if you’re not familiar, manufactures, and services control solutions for the aerospace and industrial markets worldwide. The company recently hit fresh highs following better-than-expected earnings results, with analysts increasing forecasts based on strong momentum in both core business segments.

Zen Rating: A (Strong Buy) see full analysis

Recent Price: $392.00 — get current quote

Max 1-year forecast: $417.00

Why we're watching:

  • Analyst support: WWD has strong analyst conviction with 6 Strong Buy ratings, 1 Buy rating, and 1 Hold rating among 8 analysts covering the stock. See the ratings
  • Truist Securities' Michael Ciarmoli (a top 1% rated analyst) recently maintained his Strong Buy rating with a $404 price target following the company's earnings beat that sent shares to new highs.
  • UBS researcher Gavin Parsons (top 10%) set the street-high $417 price target, maintaining his Strong Buy rating as Woodward continues to demonstrate strong execution in aerospace and industrial control systems.
  • Industry ranking context: WWD is currently the 3rd highest-rated stock in the Defense industry, which has an Industry Rating of C.
  • Zen Rating highlights: With a Zen Rating of A (Strong Buy), WWD is in the top 5% of stocks we track overall — a grade that has historically resulted in outperformance.
  • Component Grades: Woodward excels with Growth at B and Artificial Intelligence at A, balanced by Value at C and Momentum at B, reflecting strong technological positioning in aerospace controls. See all 7 Zen Component Grades here

3. FedEx (NYSE: FDX)

The logistics leader is positioned to capitalize on e-commerce growth and international expansion, recently announcing a consortium to acquire parcel-delivery provider InPost for $9.2 billion.

Zen Rating: A (Strong Buy)see full analysis

Recent Price: $368.89 — get current quote

Max 1-year forecast: $412.00

Why we're watching:

  • Analyst support: FedEx commands significant Wall Street attention with 10 Strong Buy ratings, 6 Hold ratings, and 1 Strong Sell rating among the 17 total analysts we track issuing ratings. See the ratings
  • Citigroup's Ariel Rosa (a top 3% rated analyst) recently maintained his Strong Buy rating with a $401 price target following strong quarterly results, stating that FedEx has presented consistent growth metrics and is set to gain from e-commerce and international expansions.
  • UBS analyst Thomas Wadewitz (top 5%) set a $412 price target, noting that expectations for strong adoption of FedEx's services among SMEs are driving revenue growth, with FDX's pricing power continuing to strengthen supported by enhanced service offerings.
  • Wells Fargo's Christian Wetherbee (top 4%) recently upgraded the stock to Strong Buy with a $380 price target, citing improving operational metrics and rising fuel surcharges as signs of recovery, with the firm focused on international expansion.
  • Industry ranking context: FDX is currently the 1st highest-rated stock in the Logistics industry, which has an Industry Rating of B.
  • Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr — with exceptional fundamentals, FDX is in this elite tier that only includes the top 5% of stocks we track.
  • Component Grades: Fedex enjoys above-average Component Grades in several key areas, including Bs for Growth, Momentum, Safety, and our proprietary AI Factor. See all 7 Zen Component Grades here

What to Do Next?

Want to get in touch? Email us at news@wallstreetzen.com.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.